DANVILLE, PA -- Researchers at Geisinger’s Obesity Institute have demonstrated that a scoring system they have developed can accurately predict the likelihood of patients being “cured” of Type 2 diabetes by gastric bypass surgery.
Doctors consider a remission lasting more than five years as a cure.
Details about the scoring system, known as DiaRem, and its success in predicting outcomes from surgery for Type 2 diabetes patients were published today in the medical journal JAMA Surgery, a publication associated with the American Medical Association.
Study author Annemarie G. Hirsch, Ph.D., MPH, said the study found that the higher the DiaRem score, the less likelihood there was that the Roux-en-y gastric bypass (RYGB) surgery would lead to a cure.
A DiaRem score, ranging from 0 to 22, is based on four factors – insulin use, age, hemoglobin A1c concentration (a measure of blood sugar) and type of anti-diabetic drug use. The DiaRem score had previously been shown to accurately predict remissions lasting at least 12 months. This further research has shown the scoring system is also a good predictor of curing Type 2 diabetes with gastric bypass surgery, Hirsch said.
Gastric bypass surgery is a highly effective treatment for type 2 diabetes, but the likelihood that a patient will have long-term remission of diabetes varies extremely from patient to patient. The DiaRem score provides a patient with a personalized prediction of whether or not they can expect long-term remission of their disease if they choose to have surgery, she said.
One of the nation’s most innovative health services organizations, Geisinger serves more than 1.5 million patients in Pennsylvania and New Jersey. The system includes 13 hospital campuses, a nearly 600,000-member health plan, two research centers and the Geisinger Commonwealth School of Medicine. Geisinger is known for its focus on caring and innovative programs including the ProvenCare® best-practice approach to maximize quality, safety and value; ProvenHealth Navigator® advanced medical home; Springboard Health® population health program to improve the health of an entire community; ProvenExperience™ to provide refunds to patients unhappy with their care experience; and Geisinger’s MyCode® Community Health Initiative, the largest healthcare system-based precision health project in the world. With more than 215,000 volunteer participants enrolled, MyCode is conducting extensive research and returning medically actionable results to participants. A physician-led organization, with approximately 32,000 employees and more than 1,800 employed physicians, Geisinger leverages an estimated $12.7 billion positive annual impact on the Pennsylvania and New Jersey economies. Repeatedly recognized nationally for integration, quality and service, Geisinger has a long-standing commitment to patient care, medical education, research and community service. For more information, visit www.geisinger.org, or connect with us on Facebook, Instagram, LinkedIn and Twitter.